• Product NameSKLB 610
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivitySKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.
• Target NameFGFR inhibitor; PDGFR inhibitor; VEGFR inhibitor
• CAS No. 1125780-41-7
• Calculated MW 415.37
• Formulation C21H16F3N3O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)C3=CC(=CC=C3)C(F)(F)F)C=C2)=C1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:FGFR; PDGFR; VEGFR
  Boling pt:
  Melting pt:
  Solubility:DMSO: 10 mM
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Shah A, Mangaonkar A. Ann PharmacOthers. 2015 Jul 16.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting